Olanzapine-induced Drug Reaction with Eosinophilia and Systemic Symptoms: Case Report and Review of the Literature

Awad A, Goh MS, Trubiano JA. Drug reaction with eosinophilia and systemic symptoms: a systematic review. J Allergy Clin Immunol Pract 2023; 11: 1856–1868.

https://doi.org/10.1016/j.jaip.2023.02.035 DOI: https://doi.org/10.1016/j.jaip.2023.02.035

Hansen E, Gallardo M, Yan A, Mital R, Jolley D, McFeeters J, et al. Risk assessment of drugs associated with DRESS syndrome based on publication frequency: a systematic review. J Am Acad Dermatol 2024; 91: 962–966.

https://doi.org/10.1016/j.jaad.2024.06.081 DOI: https://doi.org/10.1016/j.jaad.2024.06.081

Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321: 156–158.

https://doi.org/10.1097/00000441-200102000-00008 DOI: https://doi.org/10.1097/00000441-200102000-00008

Penchilaiya V, Kuppili PP, Preeti K, Bharadwaj B. DRESS syndrome: addressing the drug hypersensitivity syndrome on combination of sodium valproate and olanzapine. Asian J Psychiatr 2017; 28: 175–176.

https://doi.org/10.1016/j.ajp.2017.05.015 DOI: https://doi.org/10.1016/j.ajp.2017.05.015

Bixby AL, Goldsborough S, Iuppa A, LeBlanc A, Schultz HE, VandenBerg A. Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. Ment Health Clin 2019; 9: 331–335.

https://doi.org/10.9740/mhc.2019.09.331 DOI: https://doi.org/10.9740/mhc.2019.09.331

Sogo A, Horiuchi H, Ueda T, Miyazaki H, Furuya R. Early-onset drug hypersensitivity syndrome in a man with pneumonia due to pre-sensitization to olanzapine. Cureus 2022; 14: e26374.

https://doi.org/10.7759/cureus.26374 DOI: https://doi.org/10.7759/cureus.26374

Sohi MK, Towne D, Mogallapu R, Chalia A, Ang-Rabanes M. A Case of olanzapine-induced cutaneous eruption. Am J Case Rep 2023; 24: e941379.

https://doi.org/10.12659/AJCR.941379 DOI: https://doi.org/10.12659/AJCR.941379

Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071–1080.

https://doi.org/10.1111/bjd.12501 DOI: https://doi.org/10.1111/bjd.12501

U.S. Food and Drug Administration (FDA). Drug Safety Communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax). 2016. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug

Teo YX, Friedmann PS, Polak ME, Ardern-Jones MR. Utility and safety of skin tests in drug reaction with eosinophilia and systemic symptoms (DRESS): a systematic review. J Allergy Clin Immunol Pract 2023; 11: 481–491e5.

https://doi.org/10.1016/j.jaip.2022.09.011 DOI: https://doi.org/10.1016/j.jaip.2022.09.011

Cordoba S, Navarro-Vidal B, Martinez-Moran C, Borbujo J. Reactivation of skin lesions after patch testing to investigate drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Actas Dermosifiliogr 2016; 107: 781–783.

https://doi.org/10.1016/j.adengl.2016.08.015 DOI: https://doi.org/10.1016/j.adengl.2016.08.015

Teo YX, Ardern-Jones MR. Reactivation of drug reaction with eosinophilia and systemic symptoms with ranitidine patch testing. Contact Dermatitis 2021; 84: 278–279.

https://doi.org/10.1111/cod.13733 DOI: https://doi.org/10.1111/cod.13733